🇺🇸 Gelsemium Sempervirens in United States

31 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 31

Most-reported reactions

1. Rash — 6 reports (19.35%)
2. Hepatitis — 4 reports (12.9%)
3. Insomnia — 4 reports (12.9%)
4. Pancreatitis — 4 reports (12.9%)
5. Headache — 3 reports (9.68%)
6. Acne — 2 reports (6.45%)
7. Drug Intolerance — 2 reports (6.45%)
8. Dyspnoea — 2 reports (6.45%)
9. Hypotension — 2 reports (6.45%)
10. Malaise — 2 reports (6.45%)

Source database →

Frequently asked questions

Is Gelsemium Sempervirens approved in United States?

Gelsemium Sempervirens does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Gelsemium Sempervirens in United States?

University Hospital, Grenoble is the originator. The local marketing authorisation holder may differ — check the official source linked above.